Drug intelligence / Profile preview

artificial tears + nonsteroidal anti-inflammatory drops

Development stage
Unknown
Lead developer
Selagine
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

This is a combination therapy consisting of artificial tears and nonsteroidal anti-inflammatory drug (NSAID) eye drops, both administered topically to the eye. Artificial tears are lubricating solutions designed to mimic natural tear film, providing moisture and relief from dry eye symptoms by supplementing or stabilizing the tear film. They are typically available over-the-counter and may contain various polymers, electrolytes, or lipids to enhance ocular surface hydration[3]. Nonsteroidal anti-inflammatory drops (such as ketorolac, nepafenac, bromfenac, diclofenac) are prescription medications that reduce ocular inflammation and pain by inhibiting cyclooxygenase enzymes involved in prostaglandin synthesis[2][4][6][7]. This combination is commonly used for symptomatic relief in conditions like dry eye disease—where artificial tears address lubrication while NSAIDs target underlying inflammation—or post-surgical recovery where both comfort and control of inflammatory processes are needed.

02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on artificial tears + nonsteroidal anti-inflammatory drops.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on artificial tears + nonsteroidal anti-inflammatory drops.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call